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Recently, the role of food and nutrition in preventing or delaying chronic disability in the elderly population has received great
attention. Thanks to their ability to influence biochemical and biological processes, bioactive nutrients are considered modifiable
factors capable of preserving a healthy brain status. A diet rich in vitamins and polyphenols and poor in saturated fatty acids has
been recommended. In the prospective of a healthy diet, cooking methods should be also considered. In fact, cooking procedures
can modify the original dietary content, contributing not only to the loss of healthy nutrients, but also to the formation of toxins,
including advanced glycation end products (AGEs).These harmful compounds are adsorbed at intestinal levels and can contribute
to the ageing process.The accumulation ofAGEs in ageing (“AGE-ing”) is further involved in the exacerbation of neurodegenerative
and many other chronic diseases. In this review, we discuss food’s dual role as both source of bioactive nutrients and reservoir for
potential toxic compounds—paying particular attention to the importance of proper nutrition in preventing/delaying Alzheimer’s
disease. In addition, we focus on the importance of a good education in processing food in order to benefit from the nutritional
properties of an optimal diet.
1. Introduction
Ageing is a major risk factor for chronic disease. Progressive
decline of biological functions can render the organism
more susceptible to endogenous or exogenous triggers,
exacerbating pathological conditions. Among the age-related
diseases, cognitive fragility and dementia remain the more
debilitating, with a pronounced impact on public health costs
arising from the need for long-term care management.
Policies that allow for the effective management of
dementia include better coordination between health and
long-term care services. However, the main goal should be
to adopt proper strategies to preserve cognitive status and/or
delay cognitive deterioration.
The degree of disability, including cognitive fragility,
depends not only on genetic susceptibility, but also on
lifestyle, environment, and triggers to which one is exposed
[1, 2]. Appropriate lifestyle behaviours, including good nutri-
tion and physical activity throughout life, are the first steps
in preventing chronic diseases and disabilities in old age
[2, 3]. Today it is well recognised that certain nutrients
derived from the diet, including polyunsaturated fatty acids
and polyphenolic compounds contained in fruits and veg-
etables, can dramatically impact the ageing brain, possibly
leading to improved cognition and motor abilities. All these
compounds exert potent antioxidant and anti-inflammatory
activity. However, their potential for improving cognition
is not limited to their antioxidant properties, as they also
involve specific molecular and cellular processes that support
brain plasticity [4]. For example, neuronal plasticity improve-
ment by omega-3 intake was found to be mediated by the
upregulation of brain-derived neurotrophic factor (BDNF)
[4, 5].
Although a healthy diet takes into account different
types of food as sources of bioactive nutrients able to pre-
serve biological functions and prevent disease development,
the contribution of different food processing and cooking
methods is often poorly considered. Indeed, the technical
manipulation of raw materials, industrial processing, and
storage and cooking methods can modify food’s original
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contents. This contributes not only to the loss of healthy
nutrients, but also to the formation of toxins—including
advanced glycation end products (AGEs) [6].
Thus, this work reviewed the impact of nutrition on
Alzheimer’s disease, the most common type of dementia,
reporting knowledge on both the contribution of bioactive
nutrients in preserving an active and healthy cognitive
state, as well as the detrimental effects of dietary-glycotoxin,
derived from food processing and cooking methods. In
addition, we focus on the importance of a good education
in processing food in order to benefit from the nutritional
properties of an optimal diet.
2. Alzheimer’s Disease
Today, nearly 46.8 million worldwide people developed
dementia, and the incidence is expected to rise in the
coming years, with 74.7 million cases estimated to occur
in 2030 and 131.5 million in 2050. After the age of 65, the
risk of developing dementia doubles every five years, and
Alzheimer’s disease (AD) affects one in four people aged
85 and over [7]. Alzheimer’s disease is a neurodegenerative
disorder characterised by progressive global deterioration
in intellect, which affects memory, thought, learning, ori-
entation, language, comprehension, and judgment, as well
as behaviour and the ability to perform everyday activities.
The major pathological hallmarks of this disease include
accumulation of protein deposits in the brain as beta-amyloid
(A𝛽) plaques and neurofibrillary tangles [8, 9]. In addition,
an AD brain exhibits constant evidence of oxidative stress-
mediated injury and widespread inflammation [10].
Alzheimer’s disease is a disorder of late life; however,
there are families in which AD is inherited as an autosomal
dominant disorder ofmidlife. Less than 1%of cases are caused
by specific mutations in three genes, which code for amyloid-
precursor protein (APP), Presenilin 1 and Presenilin 2, all
linked to amyloid-beta metabolism [9].
AD has to face two major challenges: the delay in
the diagnosis and the lack of neuroprotective or curative
pharmacological treatment. In fact, AD is recognised only
in the late stage when cognitive symptoms appear, and cur-
rently approved drugs only provide modest and temporary
relief for symptoms such as memory loss. Today, it is well
accepted that a prodromal phase ranging from 10 to 20 years
precedes the symptomatic state. During this long period,
many biochemical changes occur in the brain, anticipating
cognitive impairment. In this preclinical phase, preventive
strategies, such as dietary modification and nutritional sup-
plementation, might reduce the global burden of AD. One
of the first links between dietary intake and incidence of
AD is represented by a large prospective population-based
cohort study (Rotterdam study) that reported an associated
lower risk with the use of cholesterol-lowering statin drug
[11]. The association of dietary fats with plasma cholesterol
levels is highly relevant because cholesterol is involved in
both generation and deposition of A𝛽 [12]. Furthermore, the
protein product of APOE-𝜀4, a recognised genetic risk factor
for AD, is the principal cholesterol transporter in the brain. In
fact, many epidemiologic data suggest that nutritional intake
can influence the development and progression of AD [13].
3. Positive Effects of Dietary Nutrients in
Preventing Cognitive Deterioration
A nutritional approach to prevent, delay, or halt the progres-
sion of AD is considered to be a promising strategy and has
therefore been widely explored [14, 15].
3.1. Polyunsaturated Fatty Acids. Numerous studies have
investigated the effects of polyunsaturated fatty acids
(PUFAs) in preventing and/or slowing AD. The potential
PUFA dietary intervention to prevent neuronal loss and
cognitive decline stems from evidence that PUFAs are critical
components of neuronal cell membranes, maintaining
membrane fluidity, which is essential for synaptic vesicle
fusion and neurotransmitter communication within neural
networks. The n-3 long chain PUFAs (n-3 LCPUFAs),
which mainly include omega-3, docosahexanoic acid
(DHA), and eicosapentaenoic acid (EPA), regulate neuronal
membrane excitability and improve the capacity for neuronal
transmission in healthy subjects, thus enhancing learning
and memory [16]. Furthermore, DHA, whose high levels in
brain indicate its essential role in this organ, is also involved
in mood and emotional state, locomotor and exploratory
activities, and cognitive functions [17].
In addition, n-3 LCPUFAs modulate the inflammatory
processes by acting at the immune system level in many
different ways through (i) the regulation of cytokines and
chemokines expression, (ii) the decrease of prostaglandins
and eicosanoids, and (iii) the induction of proresolutive
factors, resolvins, and protectins that are involved in the
resolution of inflammation [5, 17, 18]. EPA, DHA, and their
bioactive mediators exert their anti-inflammatory effects not
only in the periphery [19] but also at the brain level [20]. Inter-
estingly, Freund Levi et al. [21] demonstrated that a diet rich
in n-3 LCPUFAs significantly increased DHA levels in the
brain, suggesting thatDHAandEPAdietary supplementation
might directly influence neuroinflammatory pathways [20].
Numerous observational studies have highlighted a pos-
sible association between dietary intake of fish and n-
3 LCPUFA and a lower risk of dementia, including AD
[13, 22, 23]. On the other hand, it has to be stressed that
studies finding limited or no clinical benefit of PUFAs on
cognitive improvement in AD patients were also reported
[24, 25]. For example, Chiu et al. [26] have demonstrated
in a double-blind placebo-controlled study that omega-3
monotherapy improved cognitive performance only in Mild
Cognitive Impairment (MCI) patients but not in AD group.
The reasonswhy no effect of omega-3 treatment was observed
in patients with moderate or advanced AD could be due
to the relatively short duration of the supplementation,
the daily dose used, the source and the origin (fish ver-
sus vegetable oil) of n-3 LCPUFA, the dietary history of
the patients, and the cognitive function assessed [18, 27].
Therefore, Hooijmans et al. [28] performed a meta-analysis
study on the effects of long-term omega-3 supplementation
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in AD animal models, confirming its well-recognised effect
in restoring cognitive performance. In particular, long-term
omega-3 supplementation decreased omega-6/omega-3 ratio,
reduced the amount of beta-amyloid, prevented neuronal
loss, and improved cognitive function in AD animal models.
Furthermore, the effects of DHA in reducing A𝛽 production
in in vitro study and AD animal models have been also
widely demonstrated [29, 30]. The mechanism involved in
the DHA-induced reduction in A𝛽 may be due to multiple
effects: changing in lipid raft structure, alterations in APP
processing, and induction of antiamyloidogenic chaperones
for APP [31]. Data accumulated so far strongly suggest that
the optimization of brain lipid profile might translate into a
realistic strategy to enhance cognitive performance and/or
to prevent neurodegenerative disorders. Therefore, in the
years to come, research effort has to be devoted to define
the optimal lipid dietary intake for the ageing brain and who
might benefit the most from it [17].
3.2. Vitamins. Vitamins are potent antioxidants.Their poten-
tiality in maintaining healthy cognition and preventing cog-
nitive decline rises by the fact that the brain is particularly
susceptible to oxidative stress damage. The brain is a major
metaboliser of oxygen, accounting for 20% of the body’s
consumption, and has relatively feeble protective antioxidant
mechanisms. In addition, it contains a large amount of
polyunsaturated peroxidisable fatty acids, along with high
levels of iron that act as a prooxidant. A free radical-enriched
environment in the brain contributes to the progressive
decline of cognitive abilities, exacerbating dementia. Vitamin
E has been intensively investigated for its role in protecting
membrane phospholipids against peroxidation. Zandi et al.
[32] demonstrated that the use of vitamin E and vitamin
C supplements in combination with food is associated with
reduced prevalence and incidence of AD. A multicentre
clinical trial on vitamin E supplementation for patients with
moderate AD demonstrated that vitamin E slowed disease
progression, thereby reducing the risk of institutionalisation
[32, 33]. However, in another study, no significant differences
in progression of AD were found in the vitamin E group
compared to the placebo group [33]. This is probably due to
the different compositions of vitamin E supplements, which
often differ from the form of vitamin E found in the diet.
Vitamin E refers to a group of fat-soluble compounds that
include eight chemical forms. Among them, 𝛾-tocopherol
and 𝛼-tocopherol are the most abundant in the diet, and 𝛼-
tocopherol is also the one that exerts antioxidant properties
[34]. In this context, Grimm et al. [35] demonstrated that 𝛿-
tocopherol, but not 𝛼-tocopherol, increased the level of A𝛽
by enhancing its production and decreasing its degradation,
worsening the pathology. Another critical issue to solve is the
optimal dose of vitamin E required to prevent or delay AD.
Therefore, more clinical trials are needed to define the proper
vitamin E composition and dosage in the treatment of this
pathology.
Vitamin D might also have an association with AD.
Observational studies offer good evidence that low vitaminD
concentration is a risk factor for developing AD, because its
concentrations have been found inversely correlated with its
risk [36]. Thus, wishing to reduce risk of AD, the Endocrine
Society recommendations of keeping vitamin D3 concentra-
tions above 75 nmol/L [36, 37] should be considered.
Furthermore, polymorphism of the vitamin D receptor
(VDR) and altered vitamin D signalling have been found
to predispose to AD development or AD-like neurodegen-
eration [38]. Interestingly, in the transgenic 5xFAD (Tg)
mice, an animal model of AD, five months of vitamin D3
supplementation enhanced learning and memory [39]. This
treatment has been demonstrated to induce the expression of
proteins involved in the immune and inflammatory response,
neurotransmitter activity, and endothelial and vascular pro-
cesses, with a significant decrease of amyloid plaques and
astrogliosis. Recently, Gangwar et al. [40] suggested that vita-
min D supplementation induced significant improvement in
cognitive performances also in subjects with senile dementia.
Other vitamins, including vitamin A and the complex of
vitamin B, were found lower in plasma/serum of geriatric
patients with cognitive impairment [41, 42]. For their role
in homocysteine metabolism, the three B vitamins (B6,
B12, and folic acid) have been correlated with age-related
cognitive fragility [43]. Previous epidemiological studies on
vitamin B and cognitive status found that older people with
elevated homocysteine levels (hyperhomocysteinaemia) tend
to have lower vitamin B status, as well as lower cognitive
tests scores [44]. Possible correlations between vitamin A
and Alzheimer’s disease were reported in in vitro studies,
demonstrating an anti-beta-amyloid oligomerization effect of
vitamin A and beta-carotene [45]. However, more clinical
work is needed to identify the potential benefit from vitamin
A and/or complex B supplementation in AD patients.
3.3. Polyphenols. The beneficial role of dietary polyphe-
nols has been suggested as potential functional food can-
didates to prevent memory decline [46]. Polyphenols are
natural substances present in plants, fruits, and vegeta-
bles. Some polyphenols, such as epigallocatechin-3-gallate
(EGCG) found in green tea, 4-O-methyl honokiol found
in Magnolia officinalis, resveratrol contained in grapes, and
ginkgolide A found in ginkgo biloba, have been suggested
to provide protection against AD. Their effects may be due
to their antioxidant and anti-inflammatory properties, but
also by their modulation of enzyme activity and regulation
of intracellular signalling pathways and gene expression [46,
47].
In fact, polyphenols, especially flavonoids, can also mod-
ulate those neuronal signalling cascades altered with ageing
by acting on ERK/CREB pathway involved in synaptic plas-
ticity and long-term potentiation, improving learning and
memory in both animals and humans [48–51]. Flavonoid
supplementations can modulate specific signalling kinases
like CaMKII and ERK, controlling the activation of CREB
and the increased expression of BDNF and NGF at the brain
level [50–52]. In fact, these compounds also exert a protective
function in the hippocampus of middle age mice preserving
and promoting the spatial learning strategies. Recently also
Bensalem et al. [53] demonstrated that a polyphenol-rich
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extract from grape and blueberry (PEGB), with high contents
of flavonoids, can facilitate the use of spatial strategies in
both adult and middle-aged mice. In these animals PEGB
supplementation was able to improve learning performance
by restoring CaMKII mRNA levels and increasing NGF
expression exactly in the hippocampus. It is noteworthy that
this is the first nutritional intervention that, even if with amix
of different polyphenols at low doses, shows a rescue effect on
those specific memory deficits [53].
Furthermore, Ono et al. [54] have further corroborated
the relevance of polyphenol supplementation for AD pre-
vention. He demonstrated that wine-related polyphenols,
including myricetin, quercetin, and kaempferol, inhibited
A𝛽 oligomer formation in a dose-dependent manner from
fresh monomeric A𝛽, as well as destabilised preformed A𝛽
oligomers in in vitro experiments. Resveratrol, another wine-
related polyphenol abundant also in berries, protects neu-
rons against A𝛽-induced toxicity and attenuates behavioural
impairment in rats [55]. Again, green tea’s polyphenols,
EGCG and epicatechin (EC), showed their neuroprotective
effects throughout the free radical scavengers on in vitro
oxidative stress and in neurotoxicity cellular models [56, 57].
Curcumin also has a potential role in the prevention and
treatment of AD. The biophenolic curcumin, isolated as the
active yellow component ofCurcuma longa, has a long history
of use in traditional Asian medicines for its potent anti-
inflammatory, antioxidant, and anticancer activities [58].
In AD animal models, curcumin reduced proinflammatory
cytokines, oxidative damage, and beta-amyloid production,
ameliorating cognitive deficits [59]. Zhang et al. [60] demon-
strated that macrophages derived from AD patients treated
with curcumin showed an improved uptake of beta-amyloid
when compared with untreated cells. In addition, curcumin
exerted an antiproliferative action onmicroglial cells prevent-
ing cytokine release. AlsoAmbegaokar et al. [61], using differ-
ent doses of curcumin in amixed colony of both neuronal and
glial rat cells, showed that curcumin stopped the proliferation
of neuroglial cells dose dependently, by differentiating them
intomature cells or inducing apoptosis, resulting in inhibiting
neuroinflammation. Furthermore, curcumin decreases the
lipoprotein oxidation and the free radicals formation in AD
and in other neurodegenerative disorders [62]. Because of its
lipophilic nature, curcumin crossed the blood-brain barrier
and reduced existing senile plaques, as demonstrated in
APPswe/PS1dE9 mice [63]. Curcumin reduces senile plaques
by binding with the A𝛽 oligomers, destabilising them and
preventing their extension [64]. However, further studies on
large populationwill be necessary in order to demonstrate the
effects of all these polyphenols in delaying or preventing AD.
4. Dietary-Advanced Glycation End Products
(d-AGEs) and Cognitive Decline
During the processing of foods, the temperature, the duration
of the heat treatment, and the food’s water content can drive
different biochemical reactions, transforming the original
content. At high heat administered for a long period of
time, we expect the loss of a high amount of water and the
degradation of heat-sensitivemicronutrients, such as vitamin
C, folates, and thiamine. In addition, higher temperatures
used for cooking induce a series of reactions that lead to the
characteristic smell, taste, and colour of the dish. Those reac-
tions are also involved in the formation of toxic secondary
products known as advanced glycation end products (AGEs).
AGEs are a heterogeneous group of compounds derived from
a nonenzymatic glycation of free amino groups of proteins,
lipids, or nucleic acids by reducing sugars and reactive
aldehydes [65]. They are also continuously formed in the
body as a part of normal metabolism under hyperglycaemic
and/or oxidative stress conditions [6, 65]. It is well known that
AGEs derived from the diet can highly contribute to the body
pool of AGEs and constitute a large amount of the total AGE
serum content. Since the half-life of AGEs is about double
the average of a cell’s life, their detrimental effects can persist
for a long time, especially in “long-lived” cells like nerve and
brain cells [66].Their toxic effects are related to their ability to
promote oxidative stress and inflammation by binding to cell
surface receptors or cross-linkingwith body proteins, altering
their structure and function [67, 68].
The most studied AGE receptor is RAGE, a single
transmembrane multiligand receptor that belongs to the
immunoglobulin superfamily [69]. RAGE receptors are
mainly expressed on vascular, endothelial, and smooth mus-
cle cells and on monocyte/macrophage membranes [69], but
also inmicroglia and astrocytes, as well as in neurons [70, 71].
Ligands of RAGE, apart from AGEs, include members of
the S100 protein family, proteins of the high mobility group
box-1 (HMGB1), prions, and amyloid-𝛽 peptides. RAGE is
implicated in the pathogenesis of several chronic diseases,
such as cardiovascular diseases, hypertension, and diabetes,
which are risk factors for AD, suggesting it might be the
molecular link that initiates a chronic positive feedback loop,
ultimately leading to AD etiology [69].
The interaction of RAGE receptors with AGEs induces
the activation of different intracellular cascades, which
involve the nuclear factor kB (NF-𝜅B) pathway and inflam-
matory mediators like tumour necrosis factor-𝛼 (TNF-𝛼),
interleukin-6, and C-reactive protein (CRP) [72]. All of
these pathways lead to increased oxidative stress and a
proinflammatory status.
Recently, different studies reported that an elevated serum
level of AGEs is associated with a faster rate of cognitive
decline [66, 73]. More specifically, increasing evidence in
the literature suggests that AGEs could be implicated in
the progression of Alzheimer’s, Parkinson’s disease, and
cerebrovascular dementia. In particular, RAGE seems to
be involved in AGE-induced oxidative stress and chronic
subclinical inflammation in the AD brain [74]. In fact,
RAGE is increased in the brains of AD patients and has
a role in regulating the transport of beta-amyloid across
the blood-brain barrier (BBB) [75]. In particular, RAGE
was found to act as cell surface receptor for A𝛽 [75, 76]
and promote the influx of circulating A𝛽 across BBB from
blood to brain, which is antagonized by LRP-1-mediated
efflux of A𝛽 [77, 78]. The interaction of AGEs with their
receptor (RAGE) activates also the proinflammatory pathway
via NF-kB. The neuroinflammation induced by AGEs can
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Figure 1: Involvement of diet and cooking methods in Alzheimer’s disease prevention.
establish a vicious circle, whereby the overregulation of
RAGE potentially increases A𝛽 influx across the BBB, leading
to an accumulation of A𝛽 in the brain [79]. Furthermore,
in the last years, a newly role of RAGE is emerging in
microglia activation. This can have some implication in AD
pathogenesis [80]. In fact, the interaction of RAGEwithA𝛽 in
activated microglia can initiate a cascade of events, resulting
in sustained generation of toxic mediators and, ultimately,
exacerbating neuroinflammation and leading to neuronal
loss [69].
Recently, Perrone et al. [81] also presented evidence for
a novel RAGE-mediated signalling in AD, which leads to
the expression of thioredoxin interacting protein (TXNIP) in
various cell types, promoting inflammation [81, 82]. TXNIP
binds to thioredoxin (TRX) and inhibits its antioxidant
activity, leading to oxidative stress [83]. Among the many
proteins under the redox control of TRX, the pleiotropic p53
was found peculiarly nitrated at its tyrosine residues in AD
blood cells [84], suggesting that alteration of RAGE-TXNIP
axis can have different downstream effects, contributing
to the complexity of the disease. Notably, both TXNIP
and RAGE may exacerbate injury and inflammation when
chronically activated, while they mediate neuronal repair
when transiently expressed [81–83]. Therefore, the RAGE-
TXNIP axis participates in AD progression by activating a
concerted action of oxidative stress, inflammation, vascular
dysfunction, and neurodegeneration. Thus, inhibition of
chronic activation of RAGE and TXNIP might efficiently
provide neuroprotection in AD [82].
Differently from RAGE, a protective role has been
ascribed to its secreted isoform, sRAGE. sRAGE lacks the
transmembrane domain and is present in human plasma,
functioning as a “decoy,” binding A𝛽 in plasma and prevent-
ing neurotoxic or proinflammatory responses of RAGE–A𝛽
interaction in microglia and neurons [77, 85].
In addition, some authors have proposed an involvement
of the imbalance in AGE clearance in AD pathology. The
serum level of AGEs is the result of their endogenous
production, exogenous dietary intake, and renal clearance.
Several enzymes (glyoxalase I and II and carbonyl reductase)
and a specific receptor (AGER1) are also involved in the
detoxification system against the prooxidant effects of glyca-
tion [67, 68]. Interestingly, in the early stage of AD, glyoxalase
I is upregulated in order tomaintain 𝛼-oxoaldehyde products
at a physiological level, while in the late stage the enzyme
is decreased. The correlation between AGE deposits and
glyoxalase I expression has been further demonstrated in
both age- and AD-affected brains [86].
Food, as both source of bioactive nutrients and reservoir
for potential toxic compounds, can have a dual role in AD
pathology (Figure 1). All these findings indicate that AGEs
can be considered as dietary risk factors not yet recognized
and important pathogenic mediators involved in AD. The
discovery of natural or pharmacological AGE inhibitors and
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the adoption of an AGE-restricted diet might be further new
challenges, in order to promote a healthy ageing status and
prevent cognitive decline exacerbation.
5. Dietary AGEs and Alzheimer’s Disease:
Association or Causality
Since Uribarri and colleagues investigated AGE content in
more than 500 dietary compounds [87, 88], cohort studies,
investigating how defined dietary patterns affect AD inci-
dence,may be revisited to extrapolate the correlation between
dietary AGE content and AD progression. Perrone and Grant
[89] in a very interesting ecological and observational study
demonstrated that both the Mediterranean diet (MeDi) and
the traditional Japanese diet help in preventingAD. Although
the traditional Japanese diet differs markedly from theMeDi,
it is also low in meat and dairy products, which contain a
high level of AGEs, suggesting a strict correlation among
lower meat intake, poor AGEs dietary, and reduced risk to
develop AD [36, 89]. In Japan, the nutritional transition from
the traditional Japanese diet to the Western diet in the last
25 years has led to an improved meat consumption with
enhancement of meat-AGEs from 24% to 52% of the total
dietary AGEs, while the AD prevalence increased from 1%
to 7% in people over 65 years [89–92]. However, whether the
increase of Japanese AD cases could be due to the enhance-
ment ofmeat consumption still has to bewell clarified. In fact,
it cannot be excluded that in the different examined cohort
studies other risk-modifying factors (trace minerals in the
brain [93], obesity rates [94], vitamin D concentrations [95],
physical activity levels [96], and alcohol consumption rates
[97]) could be also changed.
To evaluate whether dietary AGEs contribute to AD
development or are just causally linked to risk of AD, Hill’s
criteria for causality in a biological system have been exam-
ined [89]. These criteria consider the strength of association,
consistent findings in different populations, temporality, bio-
logical gradient, plausibility (e.g., mechanisms), and exper-
iment (e.g., randomized controlled trials or animal model
studies) [89, 98]. In the context of dietary AGEs and AD
risk, several of Hill’s criteria have been satisfied and clearly
indicate that AGEs,mostly in associationwith increasedmeat
consumption, can be considered risk-modifying factors for
AD pathology [36, 89].
6. Good Tips for a Healthy Low-AGE Diet
Many studies have demonstrated that a high-AGE diet pro-
motes oxidative stress and increases proinflammatory mark-
ers in chronic conditions and neurodegenerative diseases.
The potential benefits of a restricted AGE diet are promising
and could offer a simple alternative therapy in the prevention
and treatment of these conditions. Over the past decade,
several clinical trials have been performed demonstrating
that the application of an AGE-restricted diet reduces not
only the systemic levels of AGEs but also the levels of markers
of oxidative stress and inflammation [87, 88]. The first line
of action is to implement the use of food with the lowest
AGE content—mainly food composed of carbohydrates (e.g.,
starches, fruits, and vegetables) instead of full-fat cheeses,
meats, and highly processed foods. For the purpose of
estimating dietary AGE intake, a large database has been
published of the AGE content of the most common foods
[88]. Currently, no official recommendations exist regarding
the acceptable range or identifying the upper limit of dietary
AGE intake. Different studies have shown that the average
intake is nearly 15,000KU/day in healthy individuals [99].
Uribarri et al. [100] have proposed that half of the current
mean AGE intake, about 7,500KU/day, could be a very realis-
tic goal. A dietaryAGE (d-AGEs) reduction of thismagnitude
has been found to significantly alter the levels of circulating
AGEs and at the same time reduce levels of oxidative stress
and inflammation markers, enhancing insulin sensitivity in
diabetic patients [65–68]. One of the difficulties with diets
at lowest AGEs content is to maintain adequate content of
other nutrients, in addition to the quality of an appetizing and
tasty meal. For example, the ICARE clinical study performed
by Pouillart et al. [101] compared two realistic and similar
diets with different AGE levels to explore the possible health
impact of dietary AGEs. The low-AGE diet, achieved by
adjusting fat intake and increasing quantities of cooked
vegetables and steam-cooked food, reduced oxidative and
inflammatory markers in healthy subjects [100].
Cooking methods and the temperature used in cooking
are two variables for reducing dietary AGE intake. Meat and
meat-derived products processed using high, dry heat, such
as in broiling, grilling, frying, and roasting, aremajor sources
of d-AGEs. Alternative cooking methods, such as boiling and
stewing, allow daily d-AGEs ingestion to be reduced by up
to 50%, while still maintaining the same primary nutrients
[99]. Uribarri et al. estimated that a 90 g chicken breast
has an AGE amount of 1,000KU when boiled, while the
AGE content increases up to 9,000KU if broiled [100]. The
cooking time can also influence theAGE content.We recently
demonstrated that overcookingMediterranean pasta doubled
the methylglyoxal content, compared to the content achieved
with the suggested cooking time [102].
On the other hand, the sparing use of herbs, condiments,
and spices like curcumin, cinnamon, parsley, thyme, and
clove can prevent cooking-inducedAGE formation. Dearlove
and colleagues [103] demonstrated that polyphenols found in
culinary herbs like sage, marjoram, tarragon, and rosemary
are potent inhibitors of fructose-mediated protein glycation.
Spice extracts, such as cloves, ground Jamaican allspice,
and cinnamon, were also found to be glycation inhibitors,
and to a greater extent compared to herb extracts [103]. In
addition, AGE formation can be prevented by pretreating
meat with an acidic solution like vinegar or lemon juice,
which interfereswith the dramatic increase inAGE formation
during high heat exposure. For example, beef marinated
for one hour in such a solution formed less than half the
amount of AGEs during cooking than untreated samples
[100]. Many other antioxidant bioactive nutrients have been
demonstrated to have antiglycation activity. The inhibition
of glycoxidation has been showed for various polyphenols,
including quercetin, genistein, tannic acid, and gallic acid
[104, 105]. Therefore, the consumption of a polyphenol-rich
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diet may attenuate protein glycation to some extent, and the
addition of polyphenols can be useful in reducing undesired
glycoxidation in food processing.
7. Conclusion
Over two thousand years ago, Hippocrates coined the phrase,
“Let food be the medicine and medicine be the food.”
Today, thatmessage has been reinforced by rigorous scientific
evidence and observational and ecological studies. Food
scientists have demonstrated the peculiar value of specific
nutrients present in food for improving cognitive status and
preventing dementia. Furthermore, findings that secondary
products derived from cooked food can accumulate over
time in the body and represent potential risk factors for
Alzheimer’s disease have provided newfound awareness of
the importance of healthy cooking methods.
Currently, the effects of low-AGE diet in preserving
cognitive ability in AD progression are not clearly under-
stood yet. However, wishing that the reduction of dietary-
glycotoxins and the intake of bioactive nutrients in prevent-
ing/delaying AD will be confirmed, nutritional intervention
might be considered a promising strategy to reduce AD
prevalence.
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